Fractyl Laboratories develops novel surgical tools for the treatment of metabolic disease. The company’s breakthrough insights in intestinal biology offer the potential to restore the health of millions and reduce the global economic burden of diseases such as type 2 diabetes (T2D). Fractyl’s lead asset, the Revita duodenal mucosal resurfacing (DMR) device, is the first minimally invasive surgical intervention capable of moving patients off of exogenous insulin and oral drug regimes. Fractyl is currently advancing global clinical development of Revita DMR by initially targeting patients with conditions resulting from insulin resistance, including T2D and nonalcoholic steatohepatitis (NASH) while also exploring the use of Revita DMR in combination with cell and gene therapy. Fractyl has established an early commercial partnership with HCA healthcare, the largest private provider in the UK, where the Revita DMR device is currently being used to treat T2D. With the current financing, the company is advancing clinical trial plans to enable FDA approval and commercialization in the US. The company was founded in 2011 by Dr. Harith Rajagopalan and Jay Caplan.

‍